OMN 6
Alternative Names: OMN-6Latest Information Update: 06 Sep 2024
Price :
$50 *
At a glance
- Originator Omnix Medical
- Class Antibacterials; Cyclic peptides
- Mechanism of Action Bacterial outer membrane protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gram-negative infections
Most Recent Events
- 28 Aug 2024 Phase-II clinical trials in Gram-negative infections in Israel (IV) (NCT06087536)
- 27 Apr 2024 Pharmacokinetic and adverse event data from a phase II trial inGram-negative infections presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ESCMI-2024)
- 17 Oct 2023 Omnix Medical plans a phase IIa trial for Gram-negative infections (IV, infusions) in 2024 (NCT06087536)